MolecuLight® Inc. exhibited for the very first time at the 26th Edition of the European Wound Management Association (EWMA) conference that took place in Bremen, German in May 11-13 2016. The conference was organized in cooperation with the Initiative Chronische Wunden e.V. (ICW) and the collaboration of German-speaking wound associations WundD·A·CH.
It was the largest exhibition in EWMA history with over 180 exhibitors and 6,000 international attendees representing over 80 Countries.
MolecuLight’s CEO, Craig Kennedy, participated as a speaker at the Wound Care Innovation Symposium that took place on May 12 at 3:15pm.
The conference theme and opening plenary session this year was PATIENTS. WOUNDS. RIGHTS.
Securing patients’ Quality of Life is a political responsibility as well as a clinical one. Patients’ access to wound care requires the collaboration of patients, professionals and policy makers. It is a corner stone of good practice in wound management and a fundamental objective of the interdisciplinary team approach.
Noteworthy sessions included New Technologies in Wound Care and Military Wounds. The former session highlighted that there is a growing development of devices and technologies to help clinicians in assessment and diagnosis as well as in prevention and treatment of chronic wounds. The Military Wounds workshop covered the similarities and differences in management between wounds in general and military (war) wounds.
What a great event and opportunity to get the European healthcare professionals to have a close look of MolecuLight i:XTM.
Click here to see where MolecuLight is exhibiting next.
The MolecuLight i:X™ Imaging Device is approved by Health Canada (Medical License #95784).
The MolecuLight i:X™ Imaging Device is pending 510(k) clearance and CE mark approval and is not approved for use in the US or EU.